3.80
+8.26%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Armata Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Armata Pharmaceuticals is based in Los Angeles, California and is incorporated in Washington. Its shares trade on NYSE under the ticker ARMP. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $173.8m. At that date it held total assets of $76.9m and shareholders' equity of −$218.6m.
We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology. We have completed three Phase 2 clinical trials to date.
We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages” have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile. We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or “superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity and potency, and believe we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 May 1994
- Employees
- 61
- Website
- armatapharma.com ↗
- Head office
- 5005 MCCONNELL AVE, LOS ANGELES, CA, 90066
- Incorporated in
- WA
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Robin KramerIndependent Chairman of the Board$329,276
- Dr. Deborah BirxChief Executive Officer, Director, since 2023$1.6m
- Mr. David HousePrincipal Financial Officer, Senior Vice President - Finance$269,438
- Dr. Pierre KymeChief Business Officer$633,640
- Mr. Jules HaimovitzIndependent Director$277,276
- Dr. Odysseas KostasIndependent Director$281,276
- Dr. Joseph PattiIndependent Director$303,276
- Dr. Todd PetersonIndependent Director$290,276
- Dr. Sarah SchlesingerIndependent Director$291,276
- Ms. Joyce AllaireInvestor Relations, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Armata Pharmaceuticals Inc possesses a robust intellectual property portfolio, comprising of various patents and proprietary technologies. This provides the company with a competitive advantage, as it ensures exclusive rights to develop, manufacture, and market innovative products in the field of phage-based therapeutics.
- With a highly skilled team and extensive research capabilities, Armata Pharmaceuticals Inc has established itself as a leader in the field of phage therapy. This expertise gives the company an edge in the development of novel treatments to combat drug-resistant bacterial infections.
- Armata Pharmaceuticals Inc enjoys a strong financial position, with sufficient funding to support its research and development activities. This allows the company to invest in cutting-edge technologies, expand its product pipeline, and explore new market opportunities.
Weaknesses
- Armata Pharmaceuticals Inc heavily relies on ongoing research and development to generate new product candidates. The success of the company is contingent on the timely and successful development of these candidates, which may be associated with uncertainties and regulatory challenges.
- Despite its expertise in phage therapy, Armata Pharmaceuticals Inc has a relatively small market presence compared to traditional pharmaceutical companies. Gaining market share and building brand recognition may pose difficulties due to intense competition and the need for widespread adoption of phage-based therapies.
Opportunities
- The increasing prevalence of drug-resistant bacterial infections creates a significant opportunity for Armata Pharmaceuticals Inc. Phage therapies offer a promising alternative to traditional antibiotics, and the company can leverage this rising demand by developing effective and safe treatment options.
- Armata Pharmaceuticals Inc can explore collaborations and strategic partnerships with academic institutions, research organizations, and pharmaceutical companies. Such alliances can further enhance research capabilities, expand market reach, and accelerate the development and commercialization of innovative phage-based therapies.
Threats
- The regulatory landscape for phage therapies is evolving, and uncertainties regarding approval processes and safety requirements may pose challenges for Armata Pharmaceuticals Inc. Adherence to stringent regulatory standards and successful clinical trials are crucial to gain market acceptance and overcome potential hurdles.
- Armata Pharmaceuticals Inc faces intense competition from established pharmaceutical companies that have already established market presence and resources. Competing with these players requires efficient marketing strategies, differentiated product offerings, and continuous innovation to attract healthcare providers and consumers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.